

EVALUATION OF THE LIPID PROFILE IN CRF PATIENTS WITH AND WITHOUT DIALYSIS

Purushottam Kumar¹, Kunal², Akriti Kumari³, Ganesh Prasad Singh⁴, Sanjay Kumar¹

¹Assistant Professor, Department of Medicine, BMIMS, Pawapuri, Nalanda, Bihar, India.

²Senior Resident, Department of Medicine, BMIMS, Pawapuri, Nalanda, Bihar, India.

³Senior Resident, Department of Biochemistry, BMIMS, Pawapuri, Nalanda, Bihar, India.

⁴Associate Professor, Department of Medicine, BMIMS, Pawapuri, Nalanda, Bihar, India.

Corresponding Author:

Dr. Sanjay Kumar, Associate Professor, Department of Medicine, BMIMS, Pawapuri, Nalanda, Bihar, India.

Abstract:

Background: Chronic renal failure (CRF) is characterized by irreversible destruction of nephrons along with decrease glomerular filtration and suppressed urine. Disturbance of lipid profile in CRF has been found associated with increased triglycerides (TG) and low high density lipids while normal level of total cholesterol (TC) and low density lipids (LDL). Dyslipidemia in CRF patients induces cardiovascular diseases (CVD); in addition, CVD in turn leads to more rapid destruction of kidney. Aim: The present study was designed to evaluate the lipid profile in CRF patients with and without dialysis. **Material and Methods:** This was a prospective type of study. Total 100 patients of CRF patients and 40 normal control subjects were recruited for the study. CRF patients were divided into two groups. Group I consisted CRF patients with dialysis and group II included CRF patients without dialysis. Normal subjects were kept under group III control group. **Results:** Results of the present study revealed that there was a significant difference between TG, HDL and VLDL of group I ($p > 0.01$) and group II ($p > 0.01$) in comparison of group III. Nevertheless, there was no significant difference between the TC and LDL of all groups. **Conclusion:** CRF patients either with dialysis or without dialysis have a great possibility of developing dyslipidemia as well as CVD. Dialysis has been found effective in reducing nitrogenous waste products in blood; however, it is notable to decrease lipid profile in CRF patients.

Keywords: Chronic renal failure, triglycerides, CVD, dialysis.

Introduction:

Chronic renal failure (CRF) is characterized by irreversible destruction of nephrons along with decrease glomerular filtration and suppressed urine.^[1] Broad spectrum signs and symptoms along with alteration of biochemical parameters are found in the case of CRF.^[2] CRF leads to disorders in cardiovascular system, gastrointestinal system, skin, skin and central nervous system.^[3] Dyslipidemia is an early disorder which develops in the starting of CRF. Most of the CRF patients suffer with dyslipidemia due to alteration in lipid metabolism as there is imbalance between synthesis and degradation of lipid metabolism.^[4,5]

Disturbance of lipid profile in CRF has been found associated with increased triglycerides(TG)and low high density lipids while normal level of total cholesterol(TC)and low density lipids (LDL). Dyslipidemia in CRF patients induces cardiovascular diseases (CVD); in addition, CVD in turn leads to more rapid destruction of kidney.^[6]Various CVD including atherosclerosis, hypertension and ischemic heart disease have been caused due to altered level of lipid profile in CRF patients. CRF progressively results in end stage renal diseases(ESRD) along with increased pathology of CVD; higher rate of morbidity and mortality due to CVD in CRF patients. Moreover, more CRF patients are likely die with CVD instead of ESRF.^[7,8]

Therefore the present study was designed to evaluate the lipid profile in CRF patients with and without dialysis.

Material and Methods:

This prospective study was conducted at Department of Medicine, at Bhagwan Mahavir Institute of Medical Sciences, Pawapuri. The study was approved by institutional research and ethical research committee Informed. consent was taken from all the participants after explaining the study protocol before the commencement of the study. The study was conducted over a period from January 2021 to April 2022.

Total 100 patients of CRF and 40 normal control subjects were recruited for the study. CRF patients were divided in to two groups. Group I consisted CRF patients with dialysis and group II included CRF patients without dialysis. Normal subjects were kept under group III control group.

Exclusion criteria for the study included obesity, hypertension, diabetes mellitus, ischemic heart disease, tuberculosis and patients on lipid lowering medicines.

Collection of sample-Fasting blood samples (5ml) were collected in tubes. After that samples were allowed to clot than samples were centrifuged to separate serum.

Biochemical estimation

Serum concentration of total cholesterol was estimated by the enzymatic CHOD-POD method.^[9] Serum concentration of triglycerides was measured by the GPO-PAP method.⁹

Serum concentration of high density lipoprotein was measured by CHOD-POD/Phosphating state method.^[9] Serum concentration of low density lipoprotein(LDL) and VLDL were measured by using the Friedewald's formula.^[9]

Statistical analysis:

All the results were presented as mean±SD. A p value<0.05 was considered as significant. Unpaired t test was used to evaluate the result of the study.

Results:**Table 1: Baseline Characteristics of Study Population**

	Group I(n=50)	Group II(n=50)	Group III(n=40)
Age(years)Mean±SD	43.77±10.74	44.55±11.56	43.66±10.4
Sex(M/F)	27/23	29/21	23/17
BMI(kg/m ²)	22.17±1.84	22.32±1.25	22.73±1.64
Urea(mg/dl)	109±26.4*	146.8±41.8*	26.3±6.76
Creatinine(mg/dl)	6.16±1.75*	12.87±3.65*	0.81±0.27

Table 2: Lipid Profile among Control and CRF Patients.

Parameters(mg/dl)	Group I(n=50)	Group II(n=50)	Group III(n=40)
TC	44.37±12.3	42.16±12.6	182.8±16.2
TG	244.3±22.4*	210.7±21.7*	146.56±17.3
HDL	28.27±7.54*	34.22±8.45*	44.7±11.34
LDL	112.3±7.2	102.3±5.6	107.5±4.6
VLDL	43.16±2.08*	41.27±3.6*	27.19±1.14

[Table1]Shows baseline characteristics of the study participants. It is evident from the [Table 1] that there was no significance difference between the age and BMI of all three groups subjects. However, there was a significant difference between the urea and creatinine of group I($p>0.01$), and group II($p>0.01$)in comparison of groupIII.Further, [Table2revealed that there was a significant difference between TG,HDL and VLDL of group I($p>0.01$)and group II($p>0.01$) in comparison of group III. Nevertheless, there was no significant difference between the TC and LDL of all groups.

Table 3: Lipid Profile between CRF Patients with or Without Hemodialysis.

	TG	TC	HDL	LDL	VLDL
CRF patients with dialysis	Increased	No change	decreased	No change	Increased
CRF patients without dialysis	Increased	No change	decreased	No change	Increased

Discussion:

CRF is one of the leading causes of morbidity and mortality through the world especially in developing countries like India. Patients suffering with CRF have high risk of CVD. Atherosclerosis and other CVD has been found associated with CRF. Moreover, most of the patients with CRF die dueto CVD instead of ESRD.^[10] Dyslipidemia is one of the most important factors which contribute to the atherosclerosis and severity of CVD in CRF patients.^[11] CRF impaired the lipid metaboloism and induces imbalance between production and destruction of lipoproteins especially HDL and TG.^[12] The present study showed there was increase of TG in patients of CRF with dialysis in comparison of CRF patients without dialysis and control subjects. The finding of the present study are consistent with the findings

of the prior studies of Aminet al,^[6] Vaziri et al,^[13] and Saland et al,^[14] as they observed similar changes in lipid profile of CRF patients on haemodialysis. It has been suggested in literature that alteration of lipid metabolism starts with the starting of CRE and manifested itself by increasing TG.^[15] Results of the present study have shown that there were significant differences between lipid profiles ($p > 0.01$) of CRF patients with haemodialysis and control subjects. These findings are similar to the findings of Gupta DK,^[16] Das BS et al,^[17] Zoccali Cand Chan et al Further,^[18,19] Janicki et al and Reddy et al also observed the similar disturbance of lipid profile in CRF patients.^[20,21] Activities of hepatic lipase and post-heparin plasma lipoprotein have been found decreased in CRF patients. Moreover, ratio of CII vs apo CIII has been found reduced. This increased level of TG may be due to increase of apo CIII as it increases the half-life of VLDL.^[22-24] Nevertheless, cause of lipolytic activity in the patients of CRF with haemodialysis is not clear yet.

Findings of the present study suggest that hemodialysis was insufficient to treat dyslipidemia in CRF patients.

Conclusion:

CRF patients either with dialysis or without dialysis have a great possibility of developing dyslipidemia as well as CVD. Dialysis has been found effective in reducing nitrogenous waste products in blood; however, it is not able to decrease lipid profile in CRF patients. The results of the present study suggest that lipid profile should be carefully observed and treated to decrease the risk of CVD in CRF patients with or without dialysis.

References:

1. Dewardener, H.E. An outline of normal and abnormal function. In: The kidney 4th edition Churchill Livingstone New York. 1986; 181-235.
2. Mathenge R.N, Mcligego, S.O., Mutua, A.K. and Otieno, L.S. The spectrum of echocardiographic findings in chronic renal failure. East African Medical Journal, 2003; 70(3):97-103.
3. Moronkola O.A, Ojediran M.M, and Amosu A. Menstrual disorder in chronic renal failure patients attending renal clinics in Ibadan, Nigeria. African Health Sciences, 2006; 6(3):155-160.
4. RR Ravichandran, et al. Hyperlipidemia in patients with chronic renal failure. Journal of Postgraduate Medicine, 1983; 29(4):212-217.
5. S. Fauci. Editor. Harrison's principles of Internal Medicine. USA: The McGraw-Hill's, 17th edition, chapter 275.
6. K Amin, et al. Pattern of Dyslipidemia in patients with CRF. Professional Medical Journal, 2006; 13(1):79-84.
7. Gomez DI, Giammonio AM, Touceda LA. Variation in the lipid profile of patients with chronic renal failure with folic acid. International Journal of Vitamin and Nutritional Resources, 2003; 73:215-220.
8. G Brosnahan, and M Fraer. Chronic Kidney Disease: Whom to Screen and How to Treat, Part 1: Definition, Epidemiology, and Laboratory Testing. Southern Medical Journal, 2010, Vol. 103, No. 2.
9. Burtis CA, Ashwood ER, Brunts DE. Teitz fundamentals of clinical chemistry. 6th ed. 422-24.

10. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, et al. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma, Without Use of the Preparative Ultracentrifuge. *Clinical Chemistry*, 1972;18(6).
11. S.K. Agarwal and R.K. Srivastava. Chronic Kidney Disease in India: Challenges and Solutions. *Nephron Clin Pract* 2009;111:c197–c203.
12. N.D. Vaziri, H. Moradi. Mechanisms of Dyslipidemia of chronic renal failure. *Hemodialysis International* 2006;10:1–7.
13. N.D. Vaziri. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. *Am J Physiol Renal Physiol* 2006;290:F262–F272.
14. J.M. Saland & H.N. Ginsberg. Lipoprotein Metabolism In Chronic Renal Insufficiency. *Pediatr Nephrol* 2007;22:1095–1112
15. Ekonoyan G. The epidemic of cardiovascular disease in patients with chronic renal disease. *American Journal of Kidney Disease*, 1998; 32:3-5.
16. Gupta DK. Hyperlipidaemia in patient with chronic renal failure. *Bombay Hospital Journal*, 1990;33:45-50.
17. Das BS, Mishra SK, and Rao DP. Serum lipid abnormalities in Uremia. *Kidney International*, 1988;19:625-637.
18. Zoccali C. Cardiovascular risk in uremia. *Nephrology Dialysis Transplant*, 2000;15:454-457.
19. Chan MK, Vergese, Zand Morehead JF. Lipid abnormalities in uremia. *Kidney International*, 1988;19:625-637.
20. K Janicki, et al. Abnormal lipoprotein metabolism in hemodialysis patients, *Annales Universitatis Mariae Curie-Skłodowska Lublin–Polonia* 2007; Vol. LXII, N1, 58 Section D.
21. E.P. Reddy, et al. 'Dyslipidemia: End Stage Renal Disease and Hemodialysis'. *The Internet Journal of Nephrology* 2009 : Volume 5 Number 1
22. M Senti, et al. Lipoprotein Abnormalities in hypolipidemic and normal demicme nonhemodialysis chronic renal failure. *Kidney Int* 1992,41:1394-9.
23. M S Elisaf, et al. Atherogenic lipid and lipoprotein in parameters in hemodialysis patients. *Dial Trans* 1995,24:642-60.
24. C. Ponticelli, et al. Lipid abnormalities in maintenance dialysis patients and renal transplant patients. *Kidney Int.* 1978,13:572-8.